HUL turns ₹70 cr bet in Wellbeing Nutrition into ₹307 cr exit

Hindustan Unilever has divested its 19.8% stake in Wellbeing Nutrition to UVS Pharma for Rs 307 crore. This move comes after HUL's initial Rs 70 crore investment in 2022. The transaction, expected to conclude by March 2026, sees Wellbeing Nutrition valued at approximately Rs 1,600 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r7hxTCY
via IFTTT

Read More

Zydus settles US Mirabegron patent dispute with Astellas for $120 million

Zydus Lifesciences and its US subsidiary have settled patent litigation with Astellas Pharma over Astellas' Myrbetriq. Zydus will pay Astellas $120 million upfront and a per-unit licensing fee on generic Mirabegron sales until September 2027. This agreement resolves all disputes and allows Zydus to continue marketing its generic version in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u2lCe6r
via IFTTT

Read More

USV Pharma leads race to buy 85% stake in Wellbeing Nutrition at Rs 1,600 crore valuation

The Mumbai-based brand, owned by Nutritionlab, counts Hindustan Unilever and Fireside Ventures among its early backers. HUL and Fireside — holding 19.8% stake each — will exit with more than fourfold returns. Both invested in Wellbeing Nutrition about three years ago when the company was valued at about Rs 350 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8v4k2bP
via IFTTT

Read More

Trial by fire: Novelis may see bigger cash flow hit

In the wake of a second devastating fire at its Oswego facility, Novelis Inc. has revised its expectations dramatically, now forecasting a staggering impact on its free cash flow. Originally bracing for a loss of $550-650 million, the company is now looking at potential damages between $1.3-1.6 billion prior to insurance compensation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UL1XGcu
via IFTTT

Read More

Zydus Life cleared to sell life-saving cancer drug; SC tells Bristol Myers to map patents

The Supreme Court has provided Zydus Lifesciences with the go-ahead to launch its cancer drug biosimilar, countering efforts by Bristol Myers Squibb to halt its progress. The court has mandated that BMS verify how Zydus's product aligns with their patent claims, with options for BMS to request provisional support from the High Court following this analysis.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Az5Lho8
via IFTTT

Read More

Warburg-Mubadala leads race to buy majority in Soframycin maker

Exciting developments are afoot as Encube Ethicals, a key player in the pharma contract manufacturing sector, approaches a significant acquisition. The frontrunners, Warburg Pincus and Mubadala, are intensifying their bids, valuing the company at approximately ₹16,500 crore. This move underscores the burgeoning interest investors have in Indian CDMO companies, fueled by global supply chain shifts and evolving US policies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x2Wz09B
via IFTTT

Read More

French pharma giant Servier to invest €15 million to launch global single-pill platform 'GATINN' in India

French pharma group Servier is expanding in India with a €15 million investment to launch GATINN, a global platform for single pill combinations (SPCs) targeting cardiometabolic and venous diseases. The India-based hub will coordinate research, manufacturing, and exports to international markets, aiming to improve patient adherence by combining multiple drugs into a single daily dose.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ePsq5ZK
via IFTTT

Read More